Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor - Full Text View

Sponsored by:	Novartis
Information provided by:	Novartis
ClinicalTrials.gov Identifier:	NCT00412061

Purpose

The purpose of this study is to evaluate whether everolimus 10 mg / day added to treatment with octreotide depot prolongs progression free survival compared to treatment with octreotide alone in patients with advanced carcinoid tumor.

Condition	Intervention	Phase
Carcinoid Tumor Malignant Carcinoid Syndrome	Drug: Octrotide with Everolimus Drug: Octrotide depot with placebo	Phase III

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	A Randomized, Double-Blind Placebo-Controlled, Multicenter Phase III Study in Patients With Advanced Carcinoid Tumor Receiving Octreotide Depot and Everolimus 10 mg/Day or Octreotide Depot and Placebo

Resource links provided by NLM:

MedlinePlus related topics: Cancer Carcinoid Tumors

Drug Information available for: Octreotide acetate Octreotide Everolimus

U.S. FDA Resources

Further study details as provided by Novartis:

Primary Outcome Measures:

Progression Free Survival (PFS)evaluated per central radiological assessment. [ Time Frame: Every 12 weeks ] [ Designated as safety issue: No ]
To characterize the PK of RAD001 and Sandostatin LAR® depot administered in combinations [ Time Frame: throughout the study ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

To evaluate best overall response rand response reduction [ Time Frame: Every 12 weeks ] [ Designated as safety issue: No ]
T compare overall survival between study arms. [ Time Frame: Every 12 weeks ] [ Designated as safety issue: No ]
To compare changes from baseline in 5-HIAA and chromogranin-A [ Time Frame: throughout the study ] [ Designated as safety issue: No ]
To determine the safety and tolerability of the combination of RAD001 plus Sandostatin LAR® depot. [ Time Frame: throughout the study ] [ Designated as safety issue: Yes ]

Estimated Enrollment:	390
Study Start Date:	December 2006
Estimated Primary Completion Date:	December 2010 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Sandostatin LAR® depot with RAD001: Experimental	Drug: Octrotide with Everolimus
Sandostatin LAR® depot with placebo: Placebo Comparator	Drug: Octrotide depot with placebo

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion criteria

Advanced (unresectable or metastatic) carcinoid tumor
Confirmed low-grade or intermediate-grade neuroendocrine carcinoma
Documented progression of disease within 12 months prior to enrollment.
Measurable disease determined by Triphasic CT scan or MRI.

Exclusion criteria

Poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma, adenocarcinoid, goblet cell carcinoma, or small cell carcinoma.
Hepatic artery embolization within the last 6 months or cryoablation of hepatic metastasis within 2 months of enrollment.
Previous treatment with mTOR inhibitors (sirolimus, temsirolimus, everolimus)
Intolerance or hypersensitivity to octreotide, everolimus, or other rapamycins.
Severe or uncontrolled medical conditions
Chronic treatment with corticosteroids or other immunosuppressive agent.
Other primary cancer within 3 years.

Other protocol-defined inclusion/exclusion criteria may apply

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00412061

Show 48 Study Locations

Sponsors and Collaborators

Novartis

Investigators

Study Chair:

Novartis

More Information

Additional Information:

Related Info This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party:	Novartis ( External Affairs )
Study ID Numbers:	CRAD001C2325
Study First Received:	December 13, 2006
Last Updated:	April 14, 2009
ClinicalTrials.gov Identifier:	NCT00412061 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by Novartis:

Cancer
Carcinoid
Tumor
Neuroendocrine

Carcinoma
Everolimus
Octreotide

Study placed in the following topic categories:

Everolimus
Carcinoid Syndrome
Immunologic Factors
Antineoplastic Agents, Hormonal
Serotonin Syndrome
Poisoning
Octreotide
Disorders of Environmental Origin
Malignant Carcinoid Syndrome
Immunosuppressive Agents

Carcinoma
Neuroendocrine Tumors
Neuroectodermal Tumors
Drug Toxicity
Neoplasms, Germ Cell and Embryonal
Neuroepithelioma
Carcinoid Tumor
Adenocarcinoma
Neoplasms, Glandular and Epithelial

Additional relevant MeSH terms:

Immunologic Factors
Antineoplastic Agents
Physiological Effects of Drugs
Neoplasms, Nerve Tissue
Disorders of Environmental Origin
Octreotide
Pathologic Processes
Neoplasms, Germ Cell and Embryonal
Syndrome
Therapeutic Uses
Everolimus
Neoplasms by Histologic Type
Disease
Antineoplastic Agents, Hormonal

Serotonin Syndrome
Poisoning
Gastrointestinal Agents
Malignant Carcinoid Syndrome
Immunosuppressive Agents
Pharmacologic Actions
Carcinoma
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms
Drug Toxicity
Carcinoid Tumor
Adenocarcinoma
Neoplasms, Glandular and Epithelial

ClinicalTrials.gov processed this record on July 02, 2009